Supernus Pharma to acquire Adamas Pharma and with it Gocovri ,which is FDA approved for Parkinson's disease
The first CVR, worth $0.50 per share, is payable upon achieving net sales of Gocovri of $150 million in any four consecutive quarters between closing and the end of 2024. The second CVR, worth $0.50 per share, is payable upon achieving net sales of Gocovri of $225 million in any four consecutive quarters between closing and the end of 2025. The transaction is expected to close in late fourth quarter 2021 or in early first quarter 2022. The transaction will provide Supernus with two marketed products: Gocovri (amantadine) extended release capsules, the first and only FDA-approved medicine indicated for the treatment of both OFF and dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy; and Osmolex ER (amantadine) extended release tablets, approved for the treatment of Parkinson’s disease and drug-induced extrapyramidal reactions in adult patients.
Related news and insights
Ocular Therapeutix, Inc. announced the FDA has approved its Supplemental New Drug Application (sNDA) to broaden the Dextenza label to add an additional indication for the treatment of ocular itching associated with allergic conjunctivitis.